Tofacitinib, a pan-JAK inhibitor, has been used to successfully treat moderate to severe, anti-TNF resistant UC, although the evidence for its use in pouchitis and CD of the pouch is minimal [102, 103]. This evidence concerns the gene TNF and pouchitis.